Cardinal Health, Inc. (CAH)
| Previous Close | 102.17 |
| Open | 100.00 |
| Bid | 102.83 x 1200 |
| Ask | 102.93 x 800 |
| Day's Range | 100.01 - 106.68 |
| 52 Week Range | 77.56 - 116.04 |
| Volume | |
| Avg. Volume | 2,244,381 |
| Market Cap | 24.974B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 40.74 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.00 (1.96%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
- Zacks
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View
Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
- Reuters
Cardinal Health lifts 2024 profit view on demand for costly specialty drugs
Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions such as cancer. Drug distributors, including rival Cencora, have been benefiting from growing sales of specialty medicines at a time when prices of generic, or copycat, versions have been falling due to intense competition. Cardinal now expects 2024 adjusted earnings in the range of $7.30 to $7.40 per share, compared with $7.20 to $7.35 per share forecast previously.
- GuruFocus.com
Cardinal Health Inc (CAH) Q3 Earnings: Surpasses Analyst EPS Forecasts and Raises FY24 Guidance
A Detailed Look at Cardinal Health's Financial Performance and Strategic Highlights
